Acute Coronary Artery Syndrome Clinical Trial
Official title:
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol is more effective than statin therapy alone in reducing plaque volume in heart arteries of patients who have already suffered an acute coronary syndrome (ACS). The study will also investigate whether this intensive approach can help increase the presence of endothelial progenitor cells (EPC), stem cells that have been shown to reduce cardiovascular (CV) events in ACS patients. This study has two phases and FDA approval for phase II has been received and all information has been updated to reflect PREMIER Phase II.
Using statins to lower blood cholesterol, and specifically LDL, is well established as a
long-term strategy to reduce CVs and even death. But the most intensive pharmacologic
lipid-lowering therapy with statins, though proven superior to standard dose regimens, is
still associated with an unacceptably high rate of recurrent CV events early after an ACS.
This study hypothesizes that for ACS patients undergoing percutaneous coronary intervention
(PCI), intensive lipid-lowering therapy consisting of statins and LDL-apheresis (ILLT) will
significantly reduce the total coronary atheroma volume of vulnerable plaque and augment
mobilization of peripherally circulating EPC colony forming units, compared to guideline
statin monotherapy (SMT). ILLT will lead to fewer CV events for these patients.
Patients presenting at four VA sites with ACS will be screened and consented before
undergoing uncomplicated PCI (balloons or stents) and intravascular ultrasound with virtual
histology (IVUS-HS). They will then be randomized into the ILLT arm or SMT arm of the study.
The ILLT group will receive one treatment of LDL-apheresis plus a daily oral 40- 80mg dose of
Atorvastatin or equivalent statin; the SMT group will only get 40-80mg Atorvastatin or
equivalent. Patients will again undergo IVUS-HS 12 weeks after enrollment to measure atheroma
volume; EPC level will also be checked.
The three-year duration of the study includes 24 months of accrual, six months of follow-up,
and 12 months of study closure and data analysis. A two-sample t-test of mean difference with
90% power and 0.65 Cohen's D effect size provides a total sample size estimate of 102.
Counting 20% drop-out rate, the sample size increases to 128.
The recent FDA recommendations regarding the design of the study have been included in the
revised study protocol:
1. The safety data will be submitted to the FDA.
2. Patients will be randomized to both LDL-apheresis and an oral daily dose of 40-80mg
Atorvastatin or equivalent statin (Intensive LDL-lowering therapy/ILLT) or a daily dose
of 40-80mg of Atorvastatin or equivalent statin without LDL-apheresis (standard statin
monotherapy/SMT) following an uncomplicated PCI.
;